Abstract: Disclosed herein, in certain embodiments, are anti-transferrin receptor antibodies, anti-transferrin receptor antibody conjugates, and pharmaceutical compositions which comprise the anti-transferrin receptor antibodies or conjugates. In some embodiments, also disclosed herein are methods of delivering a payload utilizing an anti-transferrin receptor antibody described herein, and methods of treatment with use of an anti-transferrin receptor antibody described herein.

Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.

Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

Abstract: Disclosed herein are antibodies directed against CRTAM, nucleic acids encoding such antibodies, host cells comprising such nucleic acids encoding the antibody, methods for preparing anti-CRTAM antibodies, and methods for the treatment of diseases, e.g., human cancers, including but not limited to small cell lung cancer, non-small cell lung cancer (including squamous carcinomas and adenocarcinomas) skin cancer including melanoma, breast cancer (including TNBC), colorectal cancer, gastric cancer, ovarian cancer, cervical cancer, prostate cancer, kidney cancer, liver cancer including hepatocellular carcinoma, pancreatic cancer, head and neck cancer, nasopharyngeal cancer, oesophageal cancer, bladder cancer and other uroepithelial cancers, stomach cancer, glioma, glioblastoma, testicular, thyroid, bone, gallbladder and bile ducts, uterine, adrenal cancers, sarcomas, GIST, neuroendocrine tumours, and haematological malignancies.

Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.

Abstract: A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.

Abstract: The present invention provides, among other things, anti-C3b antibodies with increased specificity and potency and methods of treating C3 glomerulopathy and other complement mediated diseases and disorders using the same.

Abstract: The present invention relates to the use of the anti-CD38 antibody felzartamab in the prophylaxis and/or treatment of antibody-mediated rejection (ABMR) of transplants. In accordance with the present invention, felzartamab is effective in the treatment of antibody-mediated renal allograft rejection.

Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.

Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: Disclosed herein an isolated neutralizing antibody, which is capable of specifically binding to chitinase-3-like protein-1 (YKL-40) and uses thereof. The neutralizing antibody can further conjugate with a metal chelator to form an antibody complex. Further, labeling the antibody complex with a radioactive metal nuclide results in formation of a radioactive antibody complex, which can be used as a contrast agent and treatment for YKL-40 over-expression-related diseases. The radioactive antibody complex can specifically bind to YKL-40, and can be used for diagnosis and the preparation of the use of the treatment for cancers related to YKL-40 over-expression.

Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.

Abstract: Provided herein are methods of treating multiple myeloma, comprising administering to a subject with multiple myeloma an inhibitor of Nuclear Receptor Binding SET Domain Protein 2 (NSD2). Also provided are methods of use wherein the multiple myeloma has previously been determined to have a 4:14 chromosome translocation (t(4;14)).

Abstract: The present invention relates to polypeptides that are capable of binding to a specific epitope on the neonatal Fc receptor (FcRn). In particular, the present invention relates to novel and improved polypeptides comprising immunoglobulin single variable domains (ISVDs), such as heavy-chain single variable domains, that are capable of binding to a specific epitope on FcRn. The invention further relates to constructs, compounds, molecules or chemical entities that comprise at least one of these ISVDs binding to a specific epitope on FcRn. The present invention further relates to methods for producing such polypeptides as well as to uses of such polypeptides for diverse applications, including but not limited to the extension of the half-life in vivo of therapeutic compounds and/or the prevention and/or treatment of a disease and/or disorder, such as but not limited to a proliferative disease, an inflammatory disease, an infectious disease or an autoimmune disease.

Abstract: The present invention relates to a conjugate in which a polypeptide capable of forming a dimer is fused to the C-terminus of the heavy chain or light chain of an antibody or fragment thereof, a composition for increasing antigen-binding avidity of an antibody in proportion to the density of a target antigen, and a method for increasing antigen-binding avidity using the same. The present invention also relates to the treatment or diagnosis of diseases using the conjugate.

Abstract: The present invention generally relates to Fab-based antibody-like binding proteins comprising three antigen-binding domains that specifically bind one or more target proteins, wherein the antibody domain interfaces are engineered so that they readily self-assemble. The disclosure also provides methods for making trispecific binding proteins and uses of such binding proteins.

Abstract: The present invention relates to a bispecific single domain antibody against PD-L1 and CD47 and uses thereof. Specifically, a single domain antibody that specifically binds to PD-L1 and CD47, immune checkpoint proteins, has been constructed, and its affinity for an immune antigen and antitumor effect have been verified, so the bispecific single domain antibody can be usefully used as an immune checkpoint inhibitor in cancer immunotherapy.

Abstract: The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotid analogues that can bind pathogenic nucleotide repeats in DNA or RNA.

Abstract: Provided are a method for producing a cellulose complex capable of substantially uniformly dispersing cellulose in a resin without adding a compatibilizer (dispersant) while maintaining the properties of cellulose, a method for producing a cellulose complex/resin composition, a cellulose complex, and a cellulose complex/resin composition. The method for producing a cellulose complex includes a mixing step of mixing cellulose having a hydroxy group with a polymer having a reactive group capable of reacting with the hydroxy group and including a nonpolar polymer as a molecular chain, and a step of bonding the hydroxy group and the reactive group.

Abstract: Provided are methods of attaching a mannose-binding C-type lectin receptor targeting moiety to a polymeric carbohydrate backbone using an amide linkage. The amide linkage may be found between a leash, such as an amine terminated leash, and the mannose-binding C-type lectin receptor targeting moieties. The compounds and compositions disclosed utilizing the amide linkage provide for highly stable compounds with a significant reduction in loss of mannose-binding C-type lectin receptor targeting moieties from the polymeric carbohydrate backbone.

Abstract: The invention provides a preparation method of high-content Ganoderma lucidum ?-glucan and an efficient and rapid detection method thereof. The preparation method comprises ethanol-trypsin pretreatment of Ganoderma lucidum fruiting body in combination with ultrasonic-assisted alkaline hydrothermal extraction of ?-glucan from Ganoderma lucidum, and purifying ?-glucan by DEAE Sephadex A-25 Sephadex column chromatography using NAOH solution as a mobile phase, to obtain high purity (?90%) of Ganoderma lucidum ?-glucan. The detection method comprises placing the extracted ?-glucan in an autoclave and performing hydrolysis with ?-(1,3)-exo-glucanase and ?-glucosidase, and detecting and analyzing the content of the prepared ?-glucan by high pressure-acid enzymatic hydrolysis-HPLC method, using glucose as a standard. The preparation method of ?-glucan has high extraction ratio.

Abstract: A method for producing a hydrogenated polymer composition including a hydrogenated conjugated diene modified polymer that has a boron-containing functional group, the method including: (1) anionically polymerizing a monomer including a conjugated diene in the presence of a reactive metal or reactive metal compound capable of causing anionic polymerization to produce a reactive terminal polymer (Z); (2) reacting the reactive terminal polymer (Z) obtained in (1) with a boric acid compound that has at least two partial structures represented by B—O—R (I), and in which at least one R bonded to an oxygen atom in the partial structure (I) has a Taft's steric parameter Es value of ?0.30 or less to obtain an unhydrogenated conjugated diene modified polymer having a boron-containing functional group; and (3) hydrogenating at least some of carbon-carbon double bonds contained in conjugated diene units included in the unhydrogenated conjugated diene modified polymer obtained in (2).

Abstract: A method for producing an aqueous dispersion of a fluorine-containing elastomer, which includes polymerizing a fluorine-containing monomer in the presence of an aqueous medium and a fluorine-containing compound (A), wherein the fluorine-containing elastomer contains a methylene group in a main chain, the fluorine-containing compound (A) is a compound represented by general formula (A): CXiXk?CXjRa—(CZ1Z2)k—Y3??(A) wherein Xi, Xj, and Xk are the same or different and are F, Cl, H, or CF3; Y3 is a hydrophilic group; Ra is a linking group; Z1 and Z2 are the same or different and are H, F, or CF3; and k is 0 or 1; provided that at least one of Xi, Xk, Xj, Ra, Z1, and Z2 includes F; and the number of carbon atoms in a portion excluding the hydrophilic group is 6 or less, and the fluorine-containing compound (A) is fed after polymerization is initiated.

Abstract: Provided are a glycidyl (meth)acrylate composition, which includes a phenolic polymerization inhibitor that is unlikely to deteriorate such that the glycidyl (meth)acrylate composition can be stably stored for a long period of time, and a method for suppressing deactivation of a phenolic polymerization inhibitor in a glycidyl (meth)acrylate resin composition. More specifically, provided are: a glycidyl (meth)acrylate composition including a glycidyl (meth)acrylate, a quaternary ammonium salt, a strong acid salt, and a phenolic polymerization inhibitor; and a method for suppressing deactivation of a phenolic polymerization inhibitor in a glycidyl (meth)acrylate composition, the method including adjusting the content of a strong acid salt in the glycidyl (meth)acrylate composition to a certain amount relative to an amount of a quaternary ammonium salt by mole.

Abstract: A method of making an ethylene-propylene (EP) copolymer includes immobilizing a metallocene catalyst on a layered double hydroxide (LDH) to form a supported metallocene catalyst complex. The method also includes mixing the supported metallocene catalyst complex in a nonpolar solvent to form a first mixture. The method further includes degassing the first mixture and saturating with a gaseous mixture of ethylene and propylene to form a second mixture. The method further includes mixing an aluminoxane catalyst with the second mixture to initiate a polymerization reaction of the ethylene and propylene to form a reaction mixture comprising the EP copolymer and separating the EP copolymer from the reaction mixture.

Abstract: Proposed is a polyolefin resin having excellent processability, toughness, and bubble stability, thereby being useful for molding into shrinkage films, agricultural films, etc. A method of preparing the same polyolefin resin is also proposed.

Abstract: Processing parameters of polypropylene and/or polyethylene are adjusted by combining them with a non-fluorinated process aid. The process aid is an oleochemical derivative and/or a wax having a viscosity of from 10 cP to 100 cP. The wax is a branched ethylene-propylene copolymer. The processing parameter, e.g., pressure at the die, or volumetric output is adjusted for the polypropylene and/or polyethylene compared to the polypropylene and/or polyethylene without the non-fluorinated process aid at the same processing conditions. The mechanical properties of an extruded polymeric article including the non-fluorinated process aid are the same or are improved compared to the same composition without the non-fluorinated polymer processing aid or one that includes a fluorinated processing aid.

Abstract: High melt strength polypropylene composition, wherein the high melt strength polypropylene composition comprises a high melt strength polypropylene, wherein the high melt strength polypropylene composition has a melt strength ?45 cN, more preferably ?50 cN, more preferably ?55 cN, even more preferably ?60 cN, even more preferably ?65 cN, wherein the melt strength is determined in accordance with ISO 16790:2005 at a temperature of 200° C., using a cylindrical capillary having a length of 20 mm and a width of 2 mm, a starting velocity v0 of 9.8 mm/s and an acceleration of 6 mm/s2 and wherein the high melt strength polypropylene composition has a melt flow rate ?1.0 and ?4.0 g/10 min as determined in accordance with ASTM D1238 (2013) at a temperature of 230° C. under a load of 2.16 kg.

Abstract: An olefin-based polymer, a film prepared from the olefin-based polymer, and preparation methods for manufacturing the olefin-based polymer and the film are disclosed. The olefin-based polymer has excellent processability, and a film prepared from the olefin-based polymer, particularly, a linear low density polyethylene film has excellent mechanical strength, in particular, drop impact strength.

Abstract: Provided are a monomer composition for producing a superabsorbent polymer film, the monomer composition comprising an acrylic acid-based monomer having acidic groups, at least part of which is neutralized, a crosslinking agent, a cellulose-based thickener, a moisturizer, a polymerization initiator, a polyvalent metal salt, and a solvent, and being capable of producing a superabsorbent polymer film showing excellent absorption performances, particularly, an improved initial absorption rate while having a thin thickness, a method of producing a superabsorbent polymer film using the same, and a superabsorbent polymer film produced therefrom.

Abstract: The present invention relates to an ultra-high molecular weight polyethylene and a process for preparing the same, said ultra-high molecular weight polyethylene has a viscosity-average molecular weight of 150-1000×104 g/mol, a metal element content of 0-50 ppm, a bulk density of 0.30-0.55 g/cm3, a true density of 0.900-0.940 g/cm3, a melting point of 140-152° C., and a crystallinity of 40-75%, and said polyethylene satisfies at least one of condition (1) and condition (2): Condition (1): tensile elasticity modulus is greater than 250 MPa, preferably greater than 280 MPa, more preferably greater than 300 MPa, Condition (2): Young's modulus is greater than 300 MPa, preferably greater than 350 MPa. The ultra-high molecular weight polyethylene has high mechanical properties, high melting point, low metal element content and ash content, and the preparation process is simple, flexible and adjustable, and the ultra-high molecular weight ethylene copolymer has a high tensile elasticity module.

Abstract: The invention relates to a high melt strength polypropylene composition comprising a high melt strength polypropylene and wherein the high melt strength polypropylene composition has a melt strength ?65 cN, wherein the melt strength is determined in accordance with ISO 16790:2005 at a temperature of 200° C., using a cylindrical capillary having a length of 20 mm and a width of 2 mm, a starting velocity v0 of 9.8 mm/s and an acceleration of 6 mm/s2.

Abstract: The process includes providing an aqueous mixture including perfluorinated monomers, a fluoroalkyl sulfinic acid or salt thereof, and an oxidizing agent capable of oxidizing the fluoroalkyl sulfinic acid or salt thereof and polymerizing the perfluorinated Nmonomers under free radical conditions to provide an aqueous dispersion of the fluoropolymer. The fluoroalkyl group has from one to three carbon atoms. The amount of perfluorooctanoic acid or salt thereof in the aqueous dispersion of the fluoropolymer as polymerized is not more than 25 nanograms per gram of the fluoropolymer. A fluoropolymer made by the process is also described.

Abstract: This invention relates to an LCST macromonomer, obtained by a reaction between an LCST telomere and a compound containing a carbon-carbon double bond. The invention also relates to an LCST copolymer, obtained by a reaction between the LCST macromonomer and a water-soluble monomer.

Abstract: A composition containing a compound represented by the following Formula (1): [in the Formula (1), R11 and R12 each independently represent a hydrogen atom or a methyl group; and R13 represents a divalent group having a polyoxyalkylene chain]; and a compound represented by the following Formula (2): [in the Formula (2), R21 and R22 each independently represent a hydrogen atom or a methyl group; and R23 represents a divalent group having a poly(meth)acrylate chain].

Abstract: A composition containing a compound represented by the following Formula (1): [in the Formula (1), R11 and R12 each independently represent a hydrogen atom or a methyl group; and R13 represents a divalent group having a polyoxyalkylene chain]; and a compound represented by the following Formula (2): [in the Formula (2), R21 and R22 each independently represent a hydrogen atom or a monovalent organic group, and R21 and R22 may be bonded to each other to form a ring; and R23 represents a hydrogen atom or a methyl group].

Abstract: A polymeric composition having the following structure: wherein: Q± is a quaternary ammonium group; R4 is a hydrocarbon group containing 1-12 carbon atoms and optionally substituted by one or more fluorine atoms; n is an integer of 1-12; x and y are molar amounts independently selected from 0.01-0.99; z is 0 or a molar amount selected from 0.01-0.99; A? is a counteranion; provided that x+y+z=1. Also described herein are anion exchange membrane fuel cells (AEMFCs) and anion exchange membrane water electrolyzers (AEMWEs) containing a polymeric composition within the scope of Formula (1), either in a membrane or as an electrode binder or both.

Abstract: Provided are a low-viscosity ultraviolet curable silicone composition capable of being used even in a surface exposure method and a lift-up method etc.; and a cured product superior in tensile strength and elongation at break.

Abstract: A (meth)acrylate-based block copolymer including a polymer block and a (meth)acrylate-based polymer block, wherein: the (meth)acrylate-based block copolymer contains 5 to 30% by mass of the polymeric block and 70 to 95% by mass of the (meth)acrylate-based polymer block with respect to 100% by mass of the (meth)acrylate-based block copolymer; the polymer block has a monomer unit derived from a monomer; when the monomer is polymerized alone, a polymer with a glass transition temperature of 80° C. or higher can be obtained; and a tensile strength at break measured in accordance with JIS K 6251 of a film obtained by immersion-molding a (meth)acrylate-based block copolymer latex containing the (meth)acrylate-based block copolymer and heat-treating at 130° C. for 30 minutes is 14 MPa or more.

Abstract: Disclosed herein are hydrogel compositions comprising a triblock copolymer having a formula A-B-A, wherein A is a polycaprolactone (PCL) block or a polyvalerolactone (PVL) block and B is a polyethylene glycol (PEG) block. Also disclosed are methods of making a hydrogel comprising providing a photoinitiator and a triblock copolymer having a formula A-B-A, wherein the triblock copolymer comprises one or more ethylenically unsaturated moieties; and photocrosslinking the triblock copolymer, thereby forming a hydrogel.

Abstract: The disclosure relates to the functionalization of a carbon-carbon backbone (CCB) polymer using a (cyclic) grafting agent, an initiator, and optionally a reversible radical trapping agent. The grafting agent and/or initiator can be particularly selected in terms of their surface energy and/or half-life, respectively, to limit or control undesirable effects associated with reactive melt-processing, such as excessive crosslinking, chain scission, or grafting agent homopolymerization, as well as to improve or control desirable effects associated with reactive melt-processing, such as improved relative graft uniformity or homogeneity on the CCB polymer. In some cases, the grafting agent can further include a functional group to impart some additional or new chemical or physical property to the CCB polymer. In some cases, the reactively melt-processed mixture includes two or more different polymers that are compatibilized via the grafting agent.

Abstract: The present disclosure relates to a thermoplastic polyurethane composition for injection molding and a method for manufacturing the same. Specifically, the thermoplastic polyurethane composition includes 0.5% by weight to 10.0% by weight of a sulfonate diol, 13% by weight to 60% by weight of an isocyanate, 30% by weight to 70% by weight of an ether-containing polyester polyol, and 5% by weight to 40% by weight of a chain extender.

Abstract: This invention provides flame retardant compositions comprised of or formed from components comprising a sulfur-containing compound and at least one isocyanate-reactive brominated flame retardant.

Abstract: A reactive mixture and method for making a moulded flexible polyurethane comprising foam having a demould time <45 seconds, said reactive mixture comprising mixing at least following ingredients at an isocyanate index in the range 40-110.

Abstract: A composition which can be cured at room temperature; and can form a heat dissipation material exhibiting an appropriate level of hardness, low adhesion force, and excellent thermal conductivity, is provided. In addition, the composition can achieve the low adhesion force, and the like without using a plasticizer or the like, or in a state where even if the plasticizer is used, the use ratio thereof is minimized. A product containing the composition, or a cured body thereof is also provided.

Abstract: A resin composition or a cured body thereof exhibiting low adhesion force to a predetermined adherend while exhibiting high thermal conductivity is provided. Also, the low adhesion force can be achieved without using an adhesion force adjusting component such as a plasticizer or in a state where the use ratio thereof is minimized. A product containing the curable composition or the cured body thereof is also provided.

Abstract: A curable composition or a thermal interface material exhibiting low adhesion force to a predetermined adherend while having a low density as well as exhibiting a high thermal conductivity is provided. It also has excellent flame retardant properties, and exhibits ejection properties and thixotropy suitable for processes in a state where halogen flame retardants or phosphorus-based flame retardants are not used, or the use ratio thereof is minimized.

Abstract: Provides a silicon containing polyisocyanate polyaddition (PIPA) polyether polyol dispersion at readily processible viscosity for use in making flexible polyurethane foams having inherent flame retardant properties that comprises polyether polyol carrier and from 10 to 25 wt. %, based on total weight of dispersion, of particles of a silicon containing (PIPA) polyether polyol having a particle size diameter wherein 90%, by volume, of the particles in dispersion have maximum PSD of from 0.1 to 3 m and that, further, contain two or more aromatic carbamate groups. Dispersion may further comprise water or blowing agent, i) one or more catalysts, and f) one or more polyisocyanates in a foam forming mixture. In addition, provides methods for making the silicon containing PIPA polyether polyol dispersion comprising forming and mixing under shear a base polyol dispersion and delaying the addition of g) one or more polyisocyantes and h) a catalyst while mixing under shear.

Abstract: A curable composition containing: a blocked isocyanate prepolymer containing a polyol compound, a polyisocyanate compound, a branching agent, and a blocking agent; an epoxy resin; and a curing agent and/or a curing accelerator, wherein the polyol compound is polytetramethylene glycol, the branching agent is a compound having at least three reactive functional groups capable of reacting with an isocyanate group, an amount by mole of the isocyanate group in the polyisocyanate compound is 2 mol or less relative to 1 mol of a total amount by mole of a hydroxy group in the polyol compound and the reactive functional groups capable of reacting with the isocyanate group in the branching agent, and an amount of the reactive functional groups in the branching agent is more than 50 mol % of the total amount of the hydroxy group in the polyol compound and the reactive functional groups in the branching agent.

Abstract: The present disclosure relates to a composition comprising: a pre-polymer having activated groups and negatively-charged functional groups on a polymeric backbone. The present disclosure also relates to a method for preparing such a composition.